- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 1,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Azithromycin, Placebos
- Drug
- Lead sponsor
- Thomas M. Lietman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 64 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- SARS CoV-2 Post-Acute Sequelae
- Interventions
- DPA-714 PET/MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- COVID-19; Immunity
- Interventions
- No intervention
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 38 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Dimas, California
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 629 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 21
- States / cities
- Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
- Conditions
- COVID-19, Coronavirus Infection, SARS CoV 2 Infection
- Interventions
- Placebo Comparator: Sterile Water, 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- COVID-19
- Interventions
- nirmatrelvir, ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Cutler Bay, Florida • DeBary, Florida + 6 more
- Conditions
- Coronavirus Disease 2019
- Interventions
- M5049, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
- Conditions
- Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Glendale, California • San Francisco, California + 10 more
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 33,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
- Conditions
- Coronavirus, COVID, COVID-19, COVID19, Corona Virus Infection, Coronavirus Infection
- Interventions
- Not listed
- Lead sponsor
- Medable Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- COVID-19, Cancer
- Interventions
- Hydroxychloroquine, Placebo, Radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- PASC Post Acute Sequelae of COVID 19, Fatigue
- Interventions
- Physical Fatigue
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
- Interventions
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Covid19
- Interventions
- Fluvoxamine, Placebo
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 91
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
- Conditions
- COVID-19
- Interventions
- COVID-19 Group Problem Solving, Standard of Care, Booster session
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- SARS-CoV 2
- Interventions
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more
- Conditions
- Chronic Health Conditions, Older Age is Associated With Increased Pathogenicity
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 1,748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19
- Interventions
- Melatonin, Placebo (Methylcellulose) capsule
- Drug · Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Torrance, California • Miami, Florida • Seattle, Washington
- Conditions
- COVID-19
- Interventions
- Merimepodib, Matching Placebo, Remdesivir
- Drug
- Lead sponsor
- ViralClear Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more